Selected article for: "disease activity and eosinophil degranulation"
Author: Kim, Chang-Keun; Callaway, Zak; Park, Jin-Sung; Nishimori, Hisashi; Ogino, Tikatoshi; Nagao, Mizuho; Fujisawa, Takao
Title: Montelukast Reduces Serum Levels of Eosinophil-Derived Neurotoxin in Preschool Asthma
  • Document date: 2018_8_30
    • ID: uzge50xu_3
    Snippet: In addition to ECP, elevated levels of another eosinophil degranulation product, eosinophilderived neurotoxin (EDN), have been noted in asthmatics, with higher levels also found during asthma exacerbation when compared to healthy patients and those with stable asthma. 12 Therefore, EDN has been suggested as a key marker for disease activity of asthma and other eosinophil-related disease. 13 To date, there are no published studies comparing differ.....
    Document: In addition to ECP, elevated levels of another eosinophil degranulation product, eosinophilderived neurotoxin (EDN), have been noted in asthmatics, with higher levels also found during asthma exacerbation when compared to healthy patients and those with stable asthma. 12 Therefore, EDN has been suggested as a key marker for disease activity of asthma and other eosinophil-related disease. 13 To date, there are no published studies comparing differential responses to the 2 types of anti-inflammatory therapies, namely ICSs and LTRAs, for preschool children with asthma. Furthermore, clinical markers for these possible differential responses have not been defined.

    Search related documents:
    Co phrase search for related documents
    • anti inflammatory therapy and disease activity: 1
    • anti inflammatory therapy and healthy patient: 1
    • asthma disease activity and disease activity: 1, 2, 3, 4
    • asthma exacerbation and disease activity: 1
    • asthma exacerbation and EDN neurotoxin: 1
    • asthma exacerbation and high level: 1, 2, 3
    • clinical marker and disease activity: 1, 2, 3
    • clinical marker and elevated level: 1
    • clinical marker and key marker: 1
    • differential response and high level: 1, 2, 3
    • disease activity and elevated level: 1, 2, 3
    • disease activity and high level: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • disease activity and key marker: 1
    • elevated level and healthy patient: 1, 2, 3
    • elevated level and high level: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • healthy patient and high level: 1, 2